ChromoGenics announces outcome in rights issue
The Board of Directors of ChromoGenics AB (“ChromoGenics” or “the Company”) today announces the outcome of the new share issue of units with preferential rights for ChromoGenics’ shareholders (the “Rights Issue”) decided by the Board of Directors on February 8, 2022. May 2021. A total of 2,410,106 units were subscribed for with the support of unit rights, corresponding to approximately 42.4 percent of the Rights Issue, and 87,448 units without support of unit rights, corresponding to approximately 1.5 percent of the Rights Issue. The remaining part of the Rights Issue, corresponding to 2,038,